Skip to main content
. 2025 Apr 3;21(1):2475594. doi: 10.1080/21645515.2025.2475594

Figure 2.

Figure 2.

DSA results: SoC (PCV13) versus PCV20, (a) costs (10% bounds), (b) QALYs (10% bounds).

Abbreviations: AC-efficacy, all-cause efficacy; DSA, deterministic sensitivity analysis; IPD, invasive pneumococcal disease; MXN, Mexican peso; PCV13, 13valent pneumococcal conjugate vaccine; PCV20, 20-valent pneumococcal conjugate vaccine; QALY, quality-adjusted life year; SoC, standard of care.